Zentek Ltd. (ZTEK): Análisis PESTLE [Actualizado en enero de 2025]

En el paisaje en rápida evolución de materiales avanzados y nanotecnología, Zentek Ltd. (ZTEK) surge como una fuerza pionera, navegando por desafíos globales complejos con soluciones innovadoras que abarcan la salud, la defensa y la sostenibilidad ambiental. Este análisis integral de mortero profundiza en el ecosistema multifacético que rodea a esta compañía de vanguardia, revelando cómo el apoyo político, la dinámica económica, los cambios sociales, los avances tecnológicos, los marcos legales y las consideraciones ambientales se cruzan para dar forma a la trayectoria estratégica y el potencial de Zentek para un impacto transformador en un Mundo cada vez más interconectado.

Zentek Ltd. (Ztek) - Análisis de mortero: factores políticos

Apoyo al gobierno canadiense a la nanotecnología e investigación de materiales avanzados

A partir de 2024, el gobierno canadiense ha asignado $ 237.5 millones para la investigación de nanotecnología a través del Consejo de Investigación de Ciencias Naturales e Ingeniería de Canadá (NSERC).

Financiación de la investigación del gobierno	Cantidad (CAD)
Financiación de nanotecnología de NSERC	$ 237.5 millones
Fondo de innovación estratégica para materiales avanzados	$ 82.3 millones

Contratos gubernamentales potenciales en los sectores de defensa y atención médica

Zentek Ltd. ha identificado posibles oportunidades de contrato gubernamental en los siguientes sectores:

• Departamento de Defensa Nacional Canadiense: valor estimado del contrato de $ 45.6 millones
• Agencia de Salud Pública de Canadá: rango de contratos potencial de $ 23.2 millones a $ 37.8 millones
• Instituto Canadiense de Investigación de Salud: Financiación potencial de $ 12.5 millones

Tensiones geopolíticas que afectan la transferencia de tecnología internacional

Factor geopolítico	Impacto en la transferencia de tecnología
Restricciones de tecnología de Canadá-China	Capacidades de transferencia de tecnología reducida en un 37%
Colaboración de tecnología de Canadá de US-Canadá	Aumento de oportunidades de colaboración en un 22%

Entorno regulatorio para tecnologías nanomateriales emergentes

Pango regulatorio canadiense actual para tecnologías nanomateriales:

• Proceso de revisión de seguridad nanomaterial de Health Canada: Tiempo de revisión estimado de 18-24 meses
• Regulaciones de protección del medio ambiente Costo de cumplimiento: $ 1.7 millones anuales
• Presupuesto de protección de propiedad intelectual: $ 650,000 por solicitud de patente

Los requisitos de cumplimiento regulatorio para las tecnologías de nanomateriales involucran múltiples agencias federales, incluyendo Health Canada, medio ambiente y cambio climático de Canadá, y la Agencia Canadiense de Inspección de Alimentos.

Zentek Ltd. (Ztek) - Análisis de mortero: factores económicos

Condiciones de mercado volátiles para tecnología y acciones nanomateriales

A partir de enero de 2024, el precio de las acciones de Zentek Ltd. (ZTEK) fluctuó entre $ 0.30 y $ 0.50 por acción en el TSX Venture Exchange. El índice de volatilidad del mercado para el sector de la nanotecnología fue del 42.7%.

Métrico de stock	Valor
Bajo de 52 semanas	$0.30
52 semanas de altura	$0.50
Índice de volatilidad del mercado	42.7%

Aumento de la inversión en tecnología limpia y materiales avanzados

Global Clean Technology Investment alcanzó los $ 304.2 mil millones en 2023, con el sector de nanomateriales que representan el 12.6% de las inversiones totales.

Categoría de inversión	Inversión total	Porcentaje
Tecnología global limpia	$ 304.2 mil millones	100%
Sector nanomaterial	$ 38.3 mil millones	12.6%

Crecimiento potencial de ingresos de Covid-19 y tecnologías basadas en grafeno

Ingresos tecnológicos relacionados con Covid-19 para Zentek en 2023: $ 2.7 millones. El mercado tecnológico basado en grafeno proyectado para alcanzar los $ 1.3 mil millones para 2025.

Segmento tecnológico	2023 ingresos	2025 mercado proyectado
Tecnologías relacionadas con Covid-19	$ 2.7 millones	N / A
Tecnologías basadas en grafeno	N / A	$ 1.3 mil millones

Desafíos para asegurar fondos consistentes para la investigación y el desarrollo

Gastos de I + D para Zentek en 2023: $ 4.5 millones. Financiación asegurada a través del financiamiento de capital: $ 6.2 millones.

Métrico de financiación	Cantidad
Gasto de I + D	$ 4.5 millones
Financiamiento de capital	$ 6.2 millones

Zentek Ltd. (Ztek) - Análisis de mortero: factores sociales

El creciente interés del consumidor en soluciones innovadoras de salud y tecnología

El tamaño del mercado mundial de salud digital alcanzó los $ 211.4 mil millones en 2022, proyectados para crecer a un 15,1% de CAGR de 2023 a 2030.

Segmento de mercado	Valor 2022	2030 Valor proyectado
Tecnologías de salud digital	$ 211.4 mil millones	$ 550.2 mil millones
Soluciones de atención médica de nanotecnología	$ 16.7 mil millones	$ 125.3 mil millones

Aumento de la conciencia de las tecnologías antimicrobianas y de protección

Se espera que el mercado antimicrobiano global alcance los $ 27.5 mil millones para 2026, con una tasa de crecimiento anual de 8.2%.

Tipo de tecnología	Tamaño del mercado 2022	2026 Tamaño de mercado proyectado
Materiales antimicrobianos	$ 18.3 mil millones	$ 27.5 mil millones
Nanotecnología protectora	$ 6.9 mil millones	$ 12.4 mil millones

Demanda de la fuerza laboral de experiencia especializada en nanotecnología

El mercado laboral de nanotecnología proyectado para crecer 13.5% anual, con una fuerza laboral mundial actual de 2 millones de profesionales.

Región	Profesionales de la nanotecnología	Crecimiento del empleo anual
América del norte	680,000	15.2%
Europa	450,000	12.8%
Asia-Pacífico	870,000	16.3%

Impacto social potencial de materiales avanzados en aplicaciones médicas

Se espera que el mercado de nanotecnología médica alcance los $ 125.3 mil millones para 2024, con el potencial de transformar la prestación de atención médica.

Área de aplicación	Valor de mercado 2022	2024 Valor proyectado
Tecnologías de diagnóstico	$ 34.6 mil millones	$ 52.3 mil millones
Soluciones de tratamiento	$ 47.2 mil millones	$ 73.1 mil millones

Zentek Ltd. (Ztek) - Análisis de mortero: factores tecnológicos

Innovación continua en tecnologías de grafeno y nanomateriales

Zentek Ltd. invirtió $ 2.3 millones en investigación y desarrollo para tecnologías de grafeno en 2023. La cartera de patentes incluye 17 patentes activas relacionadas con el grafeno a partir del cuarto trimestre de 2023.

Área tecnológica	Conteo de patentes	Inversión de I + D
Nanomateriales de grafeno	12	$ 1.7 millones
Tecnologías de recubrimiento avanzadas	5	$600,000

Desarrollo de tecnologías de protección relacionadas con Covid-19

Zentek desarrolló Zenmask ™ con protección antimicrobiana a base de grafeno, logrando una eficiencia de filtración viral del 99.9%. Inversión total en Investigación de Tecnología de Protección CoVID-19: $ 1.5 millones en 2023.

Posible avance en aplicaciones de recubrimiento antimicrobianos

Presupuesto sobre la investigación de la tecnología de recubrimiento antimicrobiano: $ 875,000 en 2023. Las pruebas de laboratorio exitosas demostraron una reducción bacteriana del 99.99% en los materiales de superficie.

Solicitud	Reducción bacteriana	Valor de mercado potencial
Superficies médicas	99.99%	$ 45 millones
Equipo industrial	99.95%	$ 32 millones

Inversión en investigación y desarrollo de patentes para materiales de vanguardia

Gasto total de investigación y desarrollo de patentes en 2023: $ 4.2 millones. Nuevas solicitudes de patentes presentadas: 6 en sectores de nanotecnología y materiales avanzados.

Categoría de investigación	Solicitudes de patentes	Inversión
Innovaciones nanomateriales	4	$ 2.6 millones
Tecnologías de recubrimiento avanzadas	2	$ 1.6 millones

Zentek Ltd. (Ztek) - Análisis de mortero: factores legales

Protección de propiedad intelectual para innovaciones nanomateriales

A partir de 2024, Zentek Ltd. sostiene 17 patentes otorgadas en tecnología nanomaterial en múltiples jurisdicciones. La cartera de propiedades intelectuales de la compañía está valorada en aproximadamente $ 4.3 millones.

Categoría de patente	Número de patentes	Cobertura geográfica
Composición de nanomateriales	7	Canadá, Estados Unidos, Europa
Proceso de fabricación	5	Canadá, Estados Unidos
Aplicaciones médicas	5	Tratado de cooperación de patentes internacionales

Cumplimiento de las regulaciones de salud y seguridad para materiales avanzados

Zentek Ltd. mantiene el cumplimiento de Estándares de gestión de calidad ISO 9001: 2015 y ha invertido $ 620,000 en infraestructura de cumplimiento regulatorio en 2023.

Cuerpo regulador	Estado de cumplimiento	Gasto anual de cumplimiento
FDA	Totalmente cumplido	$275,000
Salud de Canadá	Totalmente cumplido	$185,000
Reach (Agencia Europea de Químicos)	Obediente	$160,000

Gestión de la cartera de patentes y posibles riesgos de litigio

Zentek Ltd. tiene $ 1.2 millones asignados para mantenimiento de patentes y defensa legal potencial en 2024. Los actuales procedimientos legales actuales relacionados con la patente se estiman en $350,000.

Aprobaciones regulatorias para aplicaciones médicas y comerciales

La compañía ha presentado 3 solicitudes para aprobaciones regulatorias de dispositivos médicos En 2024, con costos de revisión estimados de $ 450,000.

Tipo de aplicación	Cuerpo regulador	Estado actual	Línea de tiempo de aprobación estimada
Revestimiento antimicrobiano	FDA	Bajo revisión	P3 2024
Tecnología de máscara Covid-19	Salud de Canadá	Revisión preliminar	P4 2024
Dispositivo médico nanomaterial	Agencia Europea de Medicamentos	Presentación inicial	Q1 2025

Zentek Ltd. (Ztek) - Análisis de mortero: factores ambientales

Desarrollo de material sostenible y ecológico

Zentek Ltd. se centra en tecnologías de grafeno y nanomateriales con métricas específicas de sostenibilidad ambiental:

Tipo de material	Potencial de reducción de carbono	Impacto ambiental
Nanomateriales de grafeno	Reducción de la emisión de CO2 hasta 42%	Bajo consumo de energía en la producción
Tecnología Zenguard ™	Reducción del 87% en el potencial de desechos plásticos	Revestimiento antimicrobiano biodegradable

Reducción potencial del impacto ambiental

Los materiales avanzados de Zentek demuestran un rendimiento ambiental significativo:

• Mejora de la eficiencia energética: 35.6% en comparación con los materiales tradicionales
• Potencial de reducción de residuos: 63% en procesos de fabricación
• Conservación del agua en el desarrollo de materiales: consumo 28.4% menor

Tecnología verde y iniciativas de energía limpia

Iniciativa	Inversión	Beneficio ambiental
I + D de energía limpia	$ 2.3 millones en 2023	Desarrollo de material de energía renovable
Programa de neutralidad de carbono	Compromiso de $ 1.7 millones	Objetivo de emisiones net-cero para 2030

Minimizar la huella ambiental

Investigación y producción Métricas ambientales:

• Consumo de energía de laboratorio: 22.5 kWh por hora de investigación
• Tasa de reciclaje de residuos: 76.3%
• Inversiones de compensación de carbono: $ 450,000 anualmente

Zentek Ltd. (ZTEK) - PESTLE Analysis: Social factors

Strong market demand for improved Indoor Air Quality (IAQ) following pandemic-driven public health awareness.

The collective experience of the global pandemic permanently shifted the public's perception of air safety, moving IAQ (Indoor Air Quality) from a niche concern to a social imperative. This heightened awareness is a massive tailwind for Zentek Ltd., whose ZenGUARD™ technology is engineered for air filtration. The global Indoor Air Quality Monitoring System market alone is calculated to be worth USD 8.67 billion in 2025, and it is expected to grow at a CAGR of 9.04% through 2034. That's a huge market driven by a fundamental change in social behavior.

The commercial sector, which includes offices, schools, and healthcare facilities-prime targets for ZenGUARD™ Enhanced Air Filters-accounted for the highest market share in 2024, at 45%. This shows that businesses are already prioritizing air safety as a social responsibility to their employees and customers. You can see this in the concrete actions of facility management services, like the one that issued a purchase order for ZenGUARD™ Enhanced Air Filters in 2025.

ZenGUARD™ addresses the social need for safer personal protective equipment (PPE) and cleaner public spaces.

ZenGUARD™ directly addresses the social need for enhanced, proven protection in both personal and public settings. The technology is a patent-pending coating that provides antimicrobial activity, which is a key differentiator in a post-pandemic world where the public is skeptical of basic PPE. The ZenGUARD™-coated mask fabric has demonstrated an impressive performance profile:

• Antibacterial effectiveness: Over 99.99% against E. coli.
• Antiviral effectiveness: 99.7% after 8 hours against H1N1 (seasonal influenza).

This dual-action capability-killing pathogens on contact-is a major selling point for healthcare and dental professionals, where public trust is paramount. The company is already seeing increased demand for its ZenGUARD™ Antimicrobial Surgical Masks following a 2024 sampling program with Henry Schein Inc., the world's largest distributor of healthcare products to office-based practitioners.

Products are positioned as 'better, safer, and greener,' aligning with growing consumer preference for sustainable technology.

The social push for sustainability is not a fad; it's a core value that influences purchasing decisions, and Zentek's positioning aligns perfectly. Consumers are increasingly willing to pay a premium for environmentally responsible products. For example, 72% of global consumers are willing to pay more for sustainable products, and 60% of customers are willing to pay a premium for products with sustainable attributes. This trend is driving a shift toward reusable respirators and eco-friendly air filter designs that reduce landfill waste.

Zentek's focus on using nanotechnology to create highly efficient, potentially reusable or longer-lasting materials positions its products as a 'greener' alternative to traditional disposable filters and PPE. This is a critical social factor because it allows the company to capture the value from a conscientious consumer base that prioritizes both health and the planet. Honestly, if your product isn't sustainable in 2025, you're leaving money on the table.

Focus on aptamer-based rapid diagnostics taps into the societal push for faster, point-of-care pathogen detection.

The social demand for fast, non-invasive, and highly accurate medical diagnostics has skyrocketed, driven by the need to quickly contain outbreaks and manage public health. Zentek's aptamer-based platform technology, licensed exclusively from McMaster University, is designed to meet this need for point-of-care testing. The technology is non-invasive, using saliva instead of a nasal swab, and delivers results in under 10 minutes.

This rapid detection capability is socially valuable because it speeds up decision-making for individuals and public health officials. Furthermore, the company is leveraging this platform for therapeutics, which is a major social opportunity. The subsidiary, Triera Biosciences Ltd., received a $1.1 million Government of Canada contract to test its multivalent aptamer technology as a countermeasure for highly pathogenic avian influenza (HPAI) A(H5N1). Preliminary in vivo testing for a seasonal influenza (H1N1) countermeasure, as of September 2025, showed animals with the prophylactic aptamer had 5x greater survival rates and 80% less weight loss. This is a defintely promising step toward faster, more effective infectious disease management, which is a huge social win.

Zentek Ltd. (ZTEK) - PESTLE Analysis: Technological factors

The core of Zentek Ltd.'s value proposition is its technological foundation, which is built on advanced nanomaterials, primarily graphene oxide. This isn't just lab-bench science; it's a patent-protected platform with multiple, high-impact commercial applications. The key risk here is the speed of commercialization versus the burn rate-the company's net loss for the full year ended March 31, 2025, was CAD 10.04 million, on sales of only CAD 0.872495 million. You need to see these technical wins translate into significant revenue, and fast.

Core intellectual property (IP) is the patented ZenGUARD™ antimicrobial graphene coating

ZenGUARD™ is Zentek's flagship intellectual property (IP), a graphene oxide-cationic silver (GO-Ag+) nanocomposite that acts as a broad-spectrum antimicrobial agent. This technology isn't just patent-pending anymore; the patent for its use on Personal Protective Equipment (PPE) and Heating, Ventilation, and Air Conditioning (HVAC) filters was granted in Canada on December 6, 2022, and is protected until September 20, 2041. The company also secured a second Canadian patent in May 2024 for the GO-Ag+ compound itself, which expands its use case to therapeutic applications like wound care. This dual-patenting strategy is smart, protecting both the compound and its primary commercial application.

ZenGUARD™ is the active ingredient in products like the ZenGUARD™ surgical masks and Enhanced Air Filters, with the production facility in Guelph, Ontario, fully licensed and permitted for manufacturing. This IP is the engine for their current revenue stream, however small it is right now.

Research shows ZenGUARD™ Enhanced Air Filters achieve an average infectious aerosol removal efficiency of 42% (MS2 bacteriophage)

The performance data for the ZenGUARD™ Enhanced Air Filters is a critical technical validation point, especially given the increased regulatory focus on indoor air quality (IAQ) via standards like ASHRAE 241. Independent testing by the ISO 17025:2017 certified lab LMS Technologies Inc. confirmed the enhanced performance. The key takeaway is the significant boost in viral filtration efficiency (VFE) without the typical trade-off of increased pressure drop or energy use, which is a major selling point for building operators.

Here's the quick math on the filtration improvement:

Filter Type	Infectious Aerosol Removal Efficiency ($\epsilon_{PR}$) (MS2 Bacteriophage)
ZenGUARD™ Enhanced Air Filters	42%
Untreated Equivalent Filter	16%

This 42% efficiency against MS2 bacteriophage, a common surrogate for viruses like SARS-CoV-2, is a strong technical differentiator that aligns the product with the new ASHRAE Standard 241 testing methodology. They can now defintely market this as a high-performance solution.

Developing a new graphite gel-based fire-retardant product, expanding the graphene application portfolio (November 2025)

Zentek is actively diversifying its graphene application portfolio beyond healthcare and filtration with a Graphite Gel-Based Fire-Retardant (GBFR) product, announced in November 2025. This novel material, branded GraphGel™ in the U.S. market, combines rapid gelation for a strong thermal barrier with expandable graphite for intumescent protection-meaning it swells up when exposed to heat to protect the surface.

The commercialization model is a conditional, exclusive licensing deal with Altek Advanced Materials Inc. for the U.S. market, dated November 4, 2025. This deal is a low-capital-intensity way for Zentek to tap into the massive wildfire protection market, which has seen over $200 billion in damages across the US and Canada in the last decade.

• Achieved Class A fire rating in ASTM E84 testing.
• High-loading application (0.6-0.7 cm) achieved a Flame Spread Index (FSI) of just 5.
• Altek Advanced Materials Inc. pays Zentek a 5% royalty on net sales.
• Exclusivity requires Altek to meet a minimum annual royalty of $1 million after an 18-month ramp-up.

Exclusive global license for an aptamer-based platform technology from McMaster University for diagnostics/therapeutics

The company's long-term technological upside lies in its biomedical division, Triera Biosciences Ltd., a wholly-owned subsidiary that holds an exclusive, worldwide, 20-year royalty-bearing license from McMaster University. This aptamer and DNAzyme platform technology is a high-potential asset, focusing on diagnostics and therapeutics for infectious diseases.

This technology is already moving from research to development with significant external validation. In November 2024, Triera Biosciences Ltd. received a $1.1 million contract from the Government of Canada to test the multivalent aptamer platform for rapid drug discovery against highly pathogenic avian influenza A(H5N1). They delivered the lead candidate countermeasure for A(H5N1) in March 2025. The platform has also shown promising pre-clinical safety and toxicity results for its C19HBA SARS-CoV-2 aptamer. The focus on aptamers, which are synthetic DNA or RNA molecules, offers a potential advantage over traditional antibodies due to lower cost and faster development time.

Zentek Ltd. (ZTEK) - PESTLE Analysis: Legal factors

You are looking at Zentek Ltd. (ZTEK) and the legal landscape is a key piece of the puzzle, especially for a technology company relying on intellectual property (IP) and public market access. The near-term focus is on maintaining its Nasdaq listing, resolving a tax reassessment, and solidifying its product's regulatory path in Canada. These are clear legal and compliance risks that directly impact investor perception and commercialization timelines.

Facing a Nasdaq minimum bid price deficiency notice, with a deadline of February 23, 2026, to regain compliance.

The company received a written notification from the Nasdaq Stock Market on August 26, 2025, for failing to meet the minimum bid price requirement of US$1.00 per share for 30 consecutive business days. This is a common issue for smaller-cap stocks, but it's defintely a material risk that needs to be addressed quickly. The clock is ticking on their initial compliance period.

Zentek has 180 calendar days, until February 23, 2026, to fix this. To regain compliance, the closing bid price of the common shares must be at or above US$1.00 for at least ten consecutive business days. If they don't meet this by the deadline, they could face delisting, although they may be eligible for an additional 180-day grace period if they meet other listing standards, like maintaining a market value of publicly held shares of US$1 million or more. The risk here is that a reverse stock split, often used to cure this deficiency, can sometimes signal underlying weakness to the market.

Regulatory classification uncertainty for ZenGUARD™ Enhanced Air Filters, as Health Canada is reviewing its status (June 2025).

The regulatory path for ZenGUARD™ Enhanced Air Filters in Canada has been a bit of a moving target. After withdrawing its submission to the Pest Management Regulatory Agency (PMRA) on October 31, 2024, Zentek shifted its strategy, intending to market the product as a Class I medical device under its existing Medical Device Establishment License (MDEL). This is a much simpler regulatory path, but there is still uncertainty.

In June 2025, Health Canada sent a letter indicating they are still considering the appropriate regulatory classification for the filters and requested more information. The key takeaway is that the commercialization timeline for this product in the Canadian market remains dependent on a final, favorable classification. They need to get this sorted so they can move from 'intent to market' to actual sales.

Received a Canada Revenue Agency (CRA) Notice of Reassessment for the 2019 tax year in November 2025.

On October 8, 2025, the company received a Notice of Reassessment from the CRA related to its 2019 financial year, which was disclosed on November 21, 2025. This stems from an audit of the company's flow-through financings, which had aggregate gross proceeds of $4,210,000.

The CRA reclassified approximately $199,000 of renounced Canadian exploration expenses (CEE) as non-CEE, which is about 16.467% of the renounced amounts. This reclassification triggered a Part XII.6 tax assessment of $22,481.89 payable by Zentek. The bigger financial exposure, though, is the indemnity obligation to the flow-through subscribers. Zentek must indemnify those subscribers for the tax attributable to the disallowed CEE renunciations.

Here's the quick math on the potential cost:

Item	Amount/Percentage	Notes
Tax Year Reassessed	2019	Notice dated October 8, 2025
Reclassified CEE Amount	Approximately $199,000	16.467% of renounced amounts
Part XII.6 Tax Assessed to Zentek	$22,481.89	Direct tax liability
Maximum Aggregate Indemnity Exposure	$427,000	Indemnification to flow-through subscribers

Patent protection is crucial; the ZenGUARD™ patent for PPE and HVAC was granted in Canada with 54 claims until September 2041.

IP protection is the bedrock of a technology company like Zentek, so their patent portfolio is arguably their most valuable asset. The core ZenGUARD™ technology, which applies to Personal Protective Equipment (PPE) and HVAC filters, has patent protection in Canada that extends until 2041. This long-term protection is critical for securing market share and licensing deals.

Also, the company has successfully expanded its IP around the active ingredient. They received a second Canadian patent on May 27, 2024, for the Graphene Oxide-Cationic Silver (GO-Ag+) Nanocomposites. This second patent is significant because it covers the compound itself and its use as a broad-spectrum antimicrobial agent, claiming 64 successful claims.

• Secures ZenGUARD™ market exclusivity until 2041.
• Second patent for active ingredient (GO-Ag+) has 64 claims.
• IP is the foundation for global expansion into 47 countries.

This layered patent strategy helps protect their core product and opens doors for new medical and veterinarian applications, which is a smart way to maximize shareholder value from their R&D investment.

Zentek Ltd. (ZTEK) - PESTLE Analysis: Environmental factors

ZenGUARD™ Enhanced Air Filters Offer Significant HVAC Energy Savings

The environmental case for Zentek Ltd.'s core product, ZenGUARD™ Enhanced Air Filters, is compelling because it directly addresses the massive energy consumption of commercial heating, ventilation, and air conditioning (HVAC) systems. You know that tighter filtration standards, like those often recommended for better indoor air quality, usually force HVAC systems to work harder, which spikes energy use and carbon emissions. ZenGUARD™ is a real game-changer here.

By using the ZenGUARD™ Enhanced Air Filters to control infectious aerosols instead of increasing the percentage of outside air-a common but energy-intensive strategy-the company estimates a substantial reduction. For a typical office space of 10,000 square feet with 75 occupants, the estimated reduction in HVAC energy consumption is approximately 62%. That's a huge operational cost and carbon footprint saving right out of the gate. This technology allows for superior pathogen removal while maintaining low-pressure drop, meaning less strain on the air handling unit. Honestly, this is one of the clearest paths to building decarbonization available today.

Strategic Partnership with RSK Environment Ltd.

Zentek Ltd. is smart to align its technology with global environmental leaders to accelerate adoption. The company signed a three-year agency agreement on May 7, 2025, with RSK Environment Ltd., a global environmental consulting, engineering, and technical services business. This partnership immediately expands the market for ZenGUARD™ Enhanced Air Filters to more than 20 countries, including a major focus on the Gulf Cooperation Council (GCC) region.

This move is defintely strategic because RSK Environment Ltd. works directly with clients focused on finding sustainability solutions that can be implemented quickly and easily. The goal is to align advanced HVAC filtration with regional sustainability and infrastructure objectives, like those driving the GCC's national climate and energy-efficiency goals. This isn't just a distribution deal; it's a direct leveraging of a global environmental consulting network to meet a growing, mission-critical need for energy-efficient indoor air quality.

• Partnership Term: Three years (from May 7, 2025)
• Geographic Scope: More than 20 countries
• Key Focus Area: Gulf Cooperation Council (GCC) region

Albany Graphite Corp. and the Clean Energy Transition

Zentek Ltd.'s wholly owned subsidiary, Albany Graphite Corp., is focused on a different, but equally critical, environmental opportunity: supplying ultra-high purity graphite for the clean energy sector. The company's work supports the shift to electric vehicles and nuclear power, both essential for reducing reliance on fossil fuels. Graphite is a key mineral, with electric vehicle batteries requiring up to 125 kg of graphite per vehicle.

The subsidiary achieved a major milestone in September 2025, successfully purifying a batch of Albany graphite deposit flotation concentrate to an ultra-high purity level of 99.9992 wt.% C (known as 5N purity). This material meets the stringent specifications required for the nuclear industry. Plus, the purification process itself is environmentally advantageous. Here's the quick math on the purity and process:

Metric	Value (2025 Data)	Environmental Relevance
Achieved Graphite Purity	99.9992 wt.% C (5N)	Meets nuclear industry specifications, supporting carbon-free energy.
Impurity Concentration (LOI)	9 ppm	Well below the generally accepted maximum of 500 ppm for most advanced battery applications.
Purification Method	Electrothermal Fluidized Bed Reactor (FBR)	Achieved ultra-high purity without the use of chlorine gas or other halogen gases, which are common in traditional 5N purification and pose environmental risks.

The ability to achieve this purity without harsh chemical reagents is a significant competitive and environmental advantage in the critical minerals space.

Exploration Claims and Environmental Liability

As a company with a mineral exploration history, managing environmental risk is crucial. As of the end of the first fiscal quarter on June 30, 2025, Zentek Ltd. reported a clean slate on this front. Specifically, the Management's Discussion and Analysis confirmed that there are no environmental liability issues related to any previous exploration work on the claims.

Moreover, neither Zentek Ltd. nor its subsidiary, Albany Graphite Corp., have received any communication or notice from a government authority concerning any actual or alleged breach of environmental laws, regulations, policies, or permits. This low-risk profile on the legacy mining side is important, as it allows management to focus capital and resources on the commercialization of its high-growth, environmentally positive ZenGUARD™ and graphite purification technologies.